Using advanced mammography techniques to assess breast cancer treatment response
Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy
This study is testing two new mammography techniques to see if they can better predict how well chemotherapy is working for people with locally advanced breast cancer.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Stony Brook University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Stony Brook, New York) |
| Trial ID | NCT06220214 on ClinicalTrials.gov |
What this trial studies
This study compares two advanced mammography techniques, contrast-enhanced digital mammography (CEDM) and contrast-enhanced digital breast tomosynthesis (CEDBT), with breast MRI to evaluate their effectiveness in predicting the response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. The Siemens MAMMOMAT device will be used to obtain both 2D and 3D images of the breast, allowing for improved detection and localization of cancer. Participants will undergo these imaging procedures over a period of up to 18 weeks as part of their treatment plan.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with invasive locally advanced breast cancer who plan to receive at least 4 cycles of neoadjuvant chemotherapy.
Not a fit: Patients who are pregnant, have allergies to the contrast agent, decreased kidney function, or diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate assessments of treatment response in breast cancer patients, potentially improving outcomes.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques for breast cancer assessment, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis with either type of invasive locally advanced breast cancer regardless of hormone receptor or Her2 status * Plan to receive at least 4 cycles of neoadjuvant chemotherapy ahead of definitive surgery Exclusion Criteria: * Pregnancy * Allergy/sensitivity to contrast agent * Decreased kidney function * Diabetes
Where this trial is running
Stony Brook, New York
- Stony Brook Breast Center — Stony Brook, New York, United States (Recruiting)
Study contacts
- Principal investigator: Alison Stopeck, MD — Stony Brook Cancer Center
- Study coordinator: Alison Stopeck, MD
- Email: alison.stopeck@stonybrookmedicine.edu
- Phone: 631-444-7217
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.